BIOLIFE SOLUTIONS INC(BLFS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,879 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
BLFS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for BIOLIFE SOLUTIONS INC (BLFS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BLFS at 41.7/100 on a 32-signal composite quality model, placing it at rank #1,879 of 2,879 stocks — the bottom half of the AI-ranked universe. BLFS scores in the top quartile across revenue growth (88.9). Areas of concern include revenue scale (18.0) and profitability (19.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BIOLIFE SOLUTIONS INC reports quarterly revenue of $27.5M, net income of $1.2M, free cash flow of $-658.0K. Top institutional holders of BLFS by reported 13-F value include BlackRock,, Casdin Capital,, Invesco Ltd., based on the most recent SEC filings. BLFS trades on the Nasdaq exchange and files with the SEC under CIK 834365. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BLFS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOLIFE SOLUTIONS INC directly from SEC EDGAR. BIOLIFE SOLUTIONS INC's 13F Pro composite quality score has ranged between 8 and 54 since 2026, currently 41.7 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.
Revenue
Q1 2026
$27.5M
Net Income
Q1 2026
$1.2M
Free Cash Flow
Q1 2026
$-658.0K
ROIC
Q1 2026
0.0%
D/E Ratio
Q1 2026
0.01
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+9.7% YoYNet Income
+70.3% YoYOperating Income
+74.0% YoYEPS (Diluted)
+71.6% YoYTotal Assets
-3.2% YoYTotal Debt
-12.4% YoYOp. Cash Flow
+167.5% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $74.6M +9.7% | $68.0M -10.8% | $76.2M -36.0% | $119.2M +147.8% | $48.1M +143.6% | $19.7M |
| Net Income | $-20.2M +70.3% | $-68.0M +51.4% | $-139.8M -1469.4% | $-8.9M -549.2% | $2.0M +107.9% | $-25.0M |
| Operating Income | $-4.5M +74.0% | $-17.2M -190.5% | $-5.9M +83.2% | $-35.2M -463.4% | $-6.2M -270.4% | $3.7M |
| EPS (Diluted) | $-0.44 +71.6% | $-1.55 +52.3% | $-3.25 -1313.0% | $-0.23 -283.3% | $-0.06 +96.2% | $-1.56 |
| Total Assets | $399.5M -3.2% | $412.7M -8.3% | $450.2M -18.8% | $554.3M +136.0% | $234.8M +416.5% | $45.5M |
| Total Debt | $26.9M -12.4% | $30.7M +11.9% | $27.4M +239.5% | $8.1M +328.9% | $1.9M | — |
| Operating Cash Flow | $8.4M +167.5% | $-12.5M -47.2% | $-8.5M -84.8% | $-4.6M -169.1% | $6.6M +183.0% | $2.3M |
AI Insight: BLFS Financial Trends
Debt slashed 84% from $32M to $5M over six quarters while revenue hit a new high of $28M in Q1 2026, but operating profitability remains elusive.
• Total debt fell from $32M in Q2 2024 to $5M in Q1 2026, an 84% reduction, dramatically strengthening the balance sheet.
• Revenue climbed from $23M in Q2 2024 to $28M in Q1 2026, with Q3 2025 and Q1 2026 both reaching $28M — the highest in the dataset.
• Operating income has oscillated between $-17M and $1M across eight quarters, never sustaining positive territory for more than one quarter.
• Operating cash flow turned slightly negative in Q1 2026 at $-0M, breaking a streak of positive OCF across the prior six quarters.
⚠ Q2 2025 showed a sharp operating loss of $-17M on $25M revenue — monitor whether similar cost spikes recur despite rising top-line.
⚠ OCF flipped to essentially zero in Q1 2026 despite $28M revenue; cash conversion quality warrants close attention next quarter.
⚠ Equity held steady at $372M in Q1 2026; with debt near zero, leverage risk is minimal — a stabilizing factor.
AI Insight: BLFS Ratio Trends
BLFS shows a recurring seasonal Q4 profitability spike but struggles to sustain positive margins in intervening quarters, with ROIC barely at breakeven in Q1 2026.
• Operating margin turned modestly positive in Q4 2024 (6.1%) and Q4 2025 (7.2%), revealing a clear seasonal profit pattern.
• Leverage has steadily declined from D/E of 0.10 in Q2–Q3 2024 to 0.01 in Q1 2026, strengthening the balance sheet.
• Q2 2025 saw a severe operating margin collapse to -65.5% and ROA of -16.4%, the worst quarter in the dataset.
• TTM operating margin stands at -15.4%, reflecting that large one-off losses overwhelm the Q4 seasonal gains on a trailing basis.
⚠ Recurring deep losses in Q2 each year (-5.6% in Q2 2024, -65.5% in Q2 2025) signal execution or demand-timing risk to monitor.
⚠ ROIC reached just 0.0% in Q1 2026 after hitting -18.1% in Q2 2025 — sustained capital returns remain unproven.
⚠ Near-zero D/E of 0.01 in Q1 2026 removes leverage risk, providing balance-sheet flexibility if losses recur.
Get alerted when BLFS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BIOLIFE SOLUTIONS INC including:
Top Institutional Holders of BLFS
BlackRock, Inc.
$116.4M6,101,765 shCasdin Capital, LLC
$113.7M5,957,165 shInvesco Ltd.
$44.8M2,348,532 shVANGUARD CAPITAL MANAGEMENT LLC
$36.6M1,917,708 shSTATE STREET CORP
$30.1M1,577,076 shFMR LLC
$28.1M1,470,252 shMASSACHUSETTS FINANCIAL SERVICES CO /MA/
$22.8M1,197,257 shFRED ALGER MANAGEMENT, LLC
$20.6M1,079,935 shDIMENSIONAL FUND ADVISORS LP
$19.8M1,035,757 shGEODE CAPITAL MANAGEMENT, LLC
$18.5M971,927 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $116.4M | 6,101,765 |
| Casdin Capital, LLC | $113.7M | 5,957,165 |
| Invesco Ltd. | $44.8M | 2,348,532 |
| VANGUARD CAPITAL MANAGEMENT LLC | $36.6M | 1,917,708 |
| STATE STREET CORP | $30.1M | 1,577,076 |
| FMR LLC | $28.1M | 1,470,252 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $22.8M | 1,197,257 |
| FRED ALGER MANAGEMENT, LLC | $20.6M | 1,079,935 |
| DIMENSIONAL FUND ADVISORS LP | $19.8M | 1,035,757 |
| GEODE CAPITAL MANAGEMENT, LLC | $18.5M | 971,927 |
More Healthcare Companies
View all Healthcare →Put BLFS on your watchlist
Track score changes the day BIOLIFE SOLUTIONS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BLFS a good stock to buy?
13F Pro's AI-powered analysis of BIOLIFE SOLUTIONS INC (BLFS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BLFS are available on the BLFS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BLFS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BLFS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIOLIFE SOLUTIONS INC's investment landscape.